Sepsis and Septic Shock: Preclinical Studies
Randomized placebo-controlled blinded clinical studies conducted in large animals confirms NucleoCapture selectively removes NETs and rescues animals from severe septic shock.
Clinically relevant model of porcine sepsis, n=18. E. coli 4 x109
CFU were infused into each animal over 3 hours. At 2 hours, extracorporeal treatment with either NucleoCapture or sham column was started for 5 hours. A clinical critical care management algorithm was used to maintain physiological parameters as in humans. Shock was significantly attenuated with the use of NucleoCapture as evidenced by reduced lactate rise, increased total noradrenaline use (11-fold lower vs sham, p<0.01,) and higher urine output (3 fold higher vs sham, p<0.05). The studies have also confirmed the safety and ease of application of NucleoCapture.
Our preclincal studies of large animals with septic shock have confirmed that the removal of NETs with NucleoCapture lead to significant improvements in hemodynamic status and shock resolution.
Marked NET Clearance with NucleoCapture up to 95% removed from Plasma
NETs were quantified in plasma sampled from before and after the NucleoCapture column using ELISA for citrullinated H3 histone-DNA complex.